Yeqing Chen News Today : Breaking News, Live Updates & Top Stories | Vimarsana

 E-Mail DURHAM, N.C. - Glioblastoma brain tumors are especially perplexing. Inevitably lethal, the tumors occasionally respond to new immunotherapies after they've grown back, enabling up to 20% of patients to live well beyond predicted survival times. What causes this effect has long been the pursuit of researchers hoping to harness immunotherapies to extend more lives. New insights from a team led by Duke's Preston Robert Tisch Brain Tumor Center provide potential answers. The team found that recurring glioblastoma tumors with very few mutations are far more vulnerable to immunotherapies ...

Credit: The Wistar Institute PHILADELPHIA -- (Jan. 12, 2021) -- Scientists at The Wistar Institute have created an advanced humanized immune system mouse model that allows them to examine resistance to immune checkpoint blockade therapies in melanoma. It has revealed a central role for mast cells. These findings were published today in the journal Nature Communications. Checkpoint inhibitors revolutionized therapeutic options for advanced melanoma. However, only a fraction of patients respond to this treatment and some relapse due to reemergence of therapy-resistant lesions. "To better unde...